• Contact us
  • Advertise with us
  • Login
Tashi Pharma
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
No Result
View All Result
Home Articles

Sharvil Patel – Driving the next growth phase of Zydus

By Khushi Masarani

PRN by PRN
May 22, 2021
in Articles
293 3
0
Sharvil Patel - Driving the next growth phase of Zydus

Sharvil Patel, joint Managing Director of Zydus Cadila Healthcare Limited

191
SHARES
455
VIEWS

Sharvil Patel is the joint Managing Director of Zydus Cadila Healthcare Limited which is India’s fourth-largest drug company and he is also Deputy Managing director of Zydus Pharmaceuticals Ltd. The multinational Pharmaceutical company, Cadila Healthcare Ltd. headquartered in Ahmedabad, Gujarat, India manufactures primarily genetic drugs and markets healthcare treatments ranging from formulations, effective pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to cosmeceuticals. The company makes effective pharmaceutical ingredients at three locations in India at Ankleshwar plants, Vadodara plant, and Patalganga plant. The Company’s products are accessible in pills, lozenges, injections, fluids, dry syrups, powders, granules, and ointments.

Sharvil is born into a family of Cadila Healthcare Ltd which has pharmaceutical scientists and innovation enthusiasts. His grandfather, Ramanbhai B Patel, founder of Cadila Laboratories with his childhood friend Indravadan Modi in 1952(69 years ago). In 1995, the company split into two parts; Raman Patel formed Cadila Healthcare while Modi named his company Cadila Pharmaceuticals. Pankaj Patel, his father is the group’s chairman and director. Pankaj Patel has always been supportive of his son’s decisions regarding his career but Sharvil had always been fascinated by science and decided to choose a profession in this path. Pankaj Patel was also encompassed in Forbes annual list of India’s richest people in the year 2004. As of 2020, Forbes estimates Patel’s net fortune at the US $3.9 billion, propelling him India’s 46th wealthiest person.

zydus cadila plant
Zydus Cadila plant

He is now a third-generation scientist-entrepreneur, very similar to his father. He got a degree in Chemical and Pharmaceutical Sciences from the University of Sunderland and then earned a doctorate from Johns Hopkins University school of medicine for his research on breast cancer at John Hopkins Bayview centre within the US. He came back to India after doing an internship with a global pharma company for a short period. His father wanted him to join the family business later after gaining experience and knowledge about his field and the company.

He was appointed deputy director in 2007 then spearheaded the ‘Healthy Billion’ internal programme that eventually incited Zydus into the billion-dollar association in 2011.

“It was a dream come true. Heading this programme gave rise to a lot of ideas into organisational growth, change and transformation,” he recalled.

Zydus posted a turnover of 9,800 crore-plus in 2015/16 and had consolidated revenues of nearly 7,100 crores in the first nine months of the financial year 2016/17. Around 39 per cent of the company’s income now comes from the US formulations business while 35 per cent comes from the Indian formulations business. About 17 of the group’s brands also feature among the highest 300 pharma brands in India, as per AIOCD AWACS (December 2016).

For Sharvil, staying invested in research has been the profound growth. Zydus was the primary Indian pharma company to launch a replacement chemical entity (NCE) two years ago called Lipaglyn, a unique drug to treat diabetic dyslipidemia in Type II diabetes and is now undergoing a Phase II trial in the US.

Zydus also launched the world’s first biosimilar of Adalimumab called Exemptia, to treat provocative arthritis. To take things forward, more than 1,200 researchers are working across eight research and development centres, focusing on small molecules, biologics, vaccines, formulation development and API process research. Understandably, Sharvil considers launching Lipaglyn and Exemptia as milestone accomplishments in his career so far.

Zydus corporate logo
Zydus corporate logo

In times of corona, the company has been working day night to produce suitable products for Covid patients. Earlier in April, the company, Zydus Cadila announced that its drug Virafin had received exclusive emergency use authorization from the Drug Controller General of India for the treatment of mild cases of Covid-19 as it confirms the reduction in need of oxygen support and improves the recovery rate of patients. Results show that patients treated with Virafin tested negative in seven days with 91.15 % effectiveness.

In July 2020, the company got permission to conduct human trials of the COVID-19 vaccine named ZyCov-D, from the Drugs Controller General of India (DCGI), Government of India. Zydus Cadila is also among the several Indian pharma companies that received licensing agreements from the Gilead sciences to produce remdesiver. The managing director of Zydus Cadila Dr Sharvil Patel recently announced the company’s Covid vaccine ZyCoV-D against the Covid-19 infection is very close to getting approved in India in May 2021. They are likely to apply for emergency usage approval this month. The company also claims the Covid vaccine to be Painless which will be very beneficial and relieving. The company plans to ramp up the vaccine’s output to 3-4 crore doses per month and is already in discussions with two other manufacturing companies for the same. Sharvil Patel has said that as soon as the approval is granted, Zydus Cadila will start the production of Covid-19 vaccines from July.

(Author of the article Khushi Masarani. Khushi is independent writer & blogger in space of Healthcare & life sciences. The views expressed in the article are solely those of the author in her private capacity)

 

Tags: Sharvil Patelzydus
Previous Post

NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment

Next Post

NATCO receives final approval for Everolimus tablets in the US market

PRN

PRN

Related Posts

environment start up
Articles

Startups Making Environment More Sustainable

by PRN
June 5, 2021
PharmEasy
Articles

PharmEasy – the online pharmacy start-up

by PRN
June 2, 2021
Mind Over Medicine
Articles

Mind Over Medicine

by PRN
May 29, 2021
MOST INNOVATIVE BIOTECH STARTUPS TO LOOK FORWARD TO IN 2021
Articles

MOST INNOVATIVE BIOTECH STARTUPS TO LOOK FORWARD IN 2021

by PRN
May 25, 2021
Mental Health
Articles

Mental Health

by PRN
May 18, 2021
Next Post
NATCO receives final approval for Everolimus tablets in the US market

NATCO receives final approval for Everolimus tablets in the US market

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

Zydus to launch Oxemia

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

March 6, 2022
FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

March 5, 2022
Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

US FDA publishes guidance on Initiation of Voluntary Recalls

March 5, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

March 5, 2022

Browse by Category

  • Articles
  • Company Focus
  • EDQM
  • EMA
  • European Commision
  • Global Pharma News
  • Guideline News
  • Health Canada
  • Indian Pharma News
  • Interview
  • Medsafe
  • MHRA
  • SAHPRA
  • US FDA
  • Webinar

Browse by Tags

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Contact us

Address:Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002.
Phone:+91 8511586232, +91 9029066605
Email:author@pharmaregnews.com

Browse by Tag

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Advertise with us

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • bioanalytical
    • Clinical
  • Webinar
  • Contact us
  • Advertise with us
  • Login

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?